Nebraska's Cannabis Growers May Wait Two More Years to Sell a Single Gram

Nebraska's medical cannabis growers did everything the state asked. They won licenses, planted crops, and started growing. Now they've been told they might wait up to two more years before they're allowed to test and sell any of it.

That's the warning that came out of the state's latest Medical Cannabis Commission meeting. This comes as regulators keep working to finalize the rules for testing, manufacturing, and distribution. And one commission member, Lorelle Mueting, said the delay shouldn't catch anyone off guard. She noted the commission had told growers the supply chain might not be ready in time for their first harvest.

Still No Path to Market

Here's the core problem. In a regulated cannabis market, testing is the gate everything else passes through. Before a single product can reach a patient, cultivators need clear rules on potency, contaminants, and lab procedures, and they need licensed labs to actually run those tests.

Nebraska has none of that yet. The state hasn't licensed testing laboratories, manufacturers, or dispensaries. So even a grower with a perfect harvest has nowhere to send it, no one to process it, and no store to sell it in. The product has a license to exist and nowhere to go.

The Clock Is Working Against the Crop

This isn't just a paperwork delay. It's a race against the plant itself. Of Nebraska's four licensed cultivators, only one, Mahamota Cultivation Co., currently has plants in the ground, with a first harvest expected within about seven weeks of the commission's October 19 meeting.

A company representative, Garrett Elting, flagged the obvious danger. Cannabis loses potency after roughly three to six months in storage, even in temperature-controlled conditions. Now line that up against a possible two-year wait. The math is absolutely brutal. The longer growers are forced to sit on their harvests, the more that product degrades, all while operating costs pile up and not a dollar of revenue comes in. The state's delay could render the earliest crops close to worthless before they're ever legal to sell.

What the Growers Are Asking For

The four cultivators aren't just venting. In an October 15 letter to the commission, they asked for concrete changes to both the testing rules and the fee structure. The fees are the sharpest point. Growers are staring down proposed annual costs totaling $36,500, which includes a $23,500 license renewal fee and a $13,000 inventory-tracking fee. They're asking regulators to defer, reduce, or phase in those charges until there's an actual path to revenue.

Two Years and Patients Still Can't Buy

Step back and remember how this started. Nebraska voters approved medical cannabis in November 2024. Nearly two years later, not one patient can legally buy medicine in the state. Regulators now expect revised rules to take effect in early 2027, with manufacturer licensing to follow, but there's still no firm date for when cultivators can actually start selling.

This article is based on reporting by Margaret Jackson for MJBizDaily, drawing on coverage from Nebraska Public Media. Read the original coverage at mjbizdaily.com.

Our take

The Slow-Motion Failure Is Right on Schedule

None of this is a surprise, and that's the damning part. When Nebraska laid out a fee structure built around a $13,000 tracking charge and a $23,500 renewal on top of it, the writing was already on the wall. A program designed to extract tens of thousands of dollars a year from businesses works fine on paper. It falls apart the moment those businesses have no legal way to earn a dollar. That's exactly where Nebraska is now. The state is sending invoices to companies it won't let operate.

Charging Rent on a Business You Won't Let Open

Think about what's actually being asked here. A grower is expected to pay $36,500 a year to hold a license for a product the state has built no way to test, process, or sell. That's not regulation. It’s literally a toll booth on a road that doesn't exist yet. The cultivators' request to defer or phase in fees isn't special pleading. It's the bare minimum any functioning program would offer businesses it has frozen in place. And the potency clock makes it worse, because every month of delay quietly destroys the value of crops already in the ground. The state isn't just withholding revenue. It's actively degrading the assets these companies bet everything on.

Who This Actually Fails

Lost in the fee fight is the person this whole program was supposed to serve: the patient. Nebraskans voted for medical cannabis two years ago, and two years later they still can't buy it. The deflection from regulators, essentially "we warned you to store your crops," puts the blame on growers for a supply chain the state itself failed to build. That's backwards. Nobody voted for a two-year wait. Nebraska is becoming the clearest case study of how a voter mandate gets slow-walked into paralysis. Worst of all, the people paying for it are the patients who were promised relief and the handful of operators naive enough to trust the timeline. Follow FSOTD for new exclusive podcast episodes and more updates directly from the culture.